Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous
Status:
Completed
Trial end date:
2017-09-11
Target enrollment:
Participant gender:
Summary
CD40 Ligand (CD40L) has been identified as a key feature in systemic lupus erythematosus
(SLE) pathogenesis, a systemic autoimmune disease characterized by a multiorgan involvement.
As platelets are a major source of soluble CD40L (sCD40L), we propose to study the effect of
clopidogrel, a platelet inhibitor, on plasmatic sCD40L levels in SLE patients.